- Home
- HOPE vs SANA Comparison
HOPE vs SANA Comparison
Compare HOPE & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HOPE | SANA |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | 1434 | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HOPE | SANA |
|---|---|---|
| Price | $12.38 | $3.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $14.50 | $7.80 |
| AVG Volume (30 Days) | 848.4K | ★ 3.6M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.53% | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.00 | N/A |
| Revenue Next Year | $19.66 | N/A |
| P/E Ratio | $52.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.44 | $1.98 |
| 52 Week High | $13.02 | $6.55 |
Technical Indicators
Market Signals| Indicator | HOPE | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 42.47 |
| Support Level | $12.21 | $3.03 |
| Resistance Level | $12.39 | $3.43 |
| Average True Range (ATR) | 0.28 | 0.20 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 61.14 | 25.00 |
Price Performance
Historical ComparisonAbout HOPE Hope Bancorp Inc.
Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services, and other banking services.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.